FILTER
FILTERED INTERVIEW RESULTS
Siva Samy
CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
"With continued investments in AI and automation, we are accelerating the industry's shift to digital validation and data-driven decision-making."
Krishna Kanumuri
CEO AND MANAGING DIRECTOR, SAI LIFE SCIENCES
"The demand for seamless phase transitions is growing, with integrated CRDMOs enabling better knowledge transfer and faster development."
Rajiv Anand
FOUNDER AND CEO, QUARTIC.AI
"Digital transformation helps accelerate drug pipelines by reducing workload and increasing efficiency."
Himanshu Gadgil
CEO, ENZENE BIOSCIENCES
"From an innovation point of view, breaking the US$40/gram cost barrier for production of mAbs is a key objective this year."
Mike Radomsky
PRESIDENT, CMC PHARMACEUTICALS
"We balance the need for speed in drug development with strict regulatory requirements by focusing on robust data, sound justifications and a well-structured technical package."
Andrea Confetti and Roberto Fanelli
EXCLUSIVE SYNTHESIS BU LEADER (AC) & CATALOGUE APIS BU LEADER (RF), DIPHARMA FRANCIS
"Small molecule drugs dominate pharmaceutical development, holding almost 60% of the market in 2024, and FDA approvals for small molecules are expected to stay strong."
Donna LaVoie
FOUNDER AND CEO, LAVOIEHEALTHSCIENCE
"For biotechs, finding the balance between appealing to the public and institutional investors will be a challenge, much like trying to balance a recipe with the right mix of ingredients for the perfect dish."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"New Jersey is home to eight of the top 10 global biopharmaceutical companies, nine of the top 10 R&D firms, and over 5,600 life sciences establishments. The State accounted for 43% of all novel FDA approvals in the past two years."
David Short
SR. MANAGER, BUSINESS DEVELOPMENT - US & CANADA, PROCOS S.P.A.
"Procos is poised for transformative growth in 2025. Our R11 facility will significantly enhance our small-scale production capacity, enabling us to meet the growing demand for high-quality, specialized APIs in the US market."
Arda Ural
PHD LIFE SCIENCES SECTOR LEADER, EY
"Heading to 2025, the outlook seems positive, particularly with US$1.3 trillion of capital available for dealmaking. This positions the industry to pursue external growth aggressively if internal pipelines fall short."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Peru Mining 2025 Pre-Release II
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
